Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 60% · prior close shown (market closed)
VERTEX PHARMACEUTICALS INC / MA shows accelerating business momentum based on AlphaOS pipeline evidence, with strong management execution.
Why it matters: Revenue +8% YoY in Q1 FY2026.
Watch: Reliance on TRIKAFTA/KAFTRIO despite growth in other products. (medium execution risk)
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 33d ago
Reported figures for VERTEX PHARMACEUTICALS INC / MA — research only, not investment advice.
Theme: ALYFTREK Commercial Ramp
Updated
What happened recently for VERTEX PHARMACEUTICALS INC / MA (VRTX) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
Prior close
$505.75
Market cap
$128.19B
Profitable
Yes
Revenue $12.00B
Net income
$3.95B
FY Dec 31, 2025
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for VERTEX PHARMACEUTICALS INC / MA — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
Follow VERTEX PHARMACEUTICALS INC / MA through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.